Onco Wiki / Indication

Sarcome de Kaposi · ligne 1 · Biktarvy — bictégravir/emtricitabine/ténofovir-AF monocomprimé ART

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Notes

STUB -- new TREATMENT-intent Indication for DIS-KAPOSI (v0.3 continuation). Distinct from the pre-existing PREVENTION-intent IND-CHRONIC-HHV8-PREVENTION-IMMUNE-RESTORATION (targets HHV-8- seropositive-but-Kaposi-sarcoma-FREE patients) -- this Indication applies to patients with a CONFIRMED Kaposi sarcoma diagnosis. Reuses the existing REG-HIV-BIKTARVY Regimen (already authored for IND-CHRONIC-HIV-PREVENTION-ART) rather than duplicating an ART regimen entity. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports". Direct inspection of that source's own KB record shows it documents only basal-cell/ squamous-cell skin cancer, not Kaposi sarcoma or HIV/ART management -- downgraded to "context" (general disease-level background, matching how dis_kaposi.yaml itself already cites it) rather than removed outright, since it is not load-bearing for this indication's actual clinical claim (ART is supported by SRC-NIH-AIDS-2024, which is genuinely an ARV guideline). Pending two-Clinical-Co-Lead signoff (CHARTER §6.1 -- dev-mode-exempted; safe to merge as draft content, NOT as published/verified clinical advice).

Utilisé par

Algorithmes

• ALGO-KAPOSI-1L - ALGO-KAPOSI-1L

Maladie

• DIS-KAPOSI - Sarcome Kaposi

Indication

• IND-KAPOSI-1L-CLASSIC-LOCAL-OBSERVATION - IND-KAPOSI-1L-CLASSIC-LOCAL-OBSERVATION